Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Showing posts with label Sovateltide. Show all posts
Showing posts with label Sovateltide. Show all posts

Monday, October 20, 2025

Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke -recruiting

 

Your competent? doctor has been working on peptides for over a decade, right? Oh NO, INCOMPETENCE REIGNED AND NOTHING WAS DONE, CORRECT?

Let's see EXACTLY HOW LONG AND IN WHAT YOUR DOCTOR IS INCOMPETENT!
  • peptide (16 posts to January 2012)
  • nerinetide (10 posts to February 2020)

    • Efficacy and Safety of Sovateltide in Patients with Acute Cerebral Ischaemic Stroke: A Randomised, Double-Blind, Placebo-Controlled, Multicentre, Phase III Clinical Trial

     November 2024

    Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke

    ClinicalTrials.gov IDNCT05691244
    SponsorPharmazz, Inc.
    Information Provided byAnil Gulati, MD, PhD
    Study Start (Actual)2025-07-24
    Primary Completion (Estimated) 2026-09
    Study Completion (Estimated)2026-11
    Enrollment (Estimated)514
    Study TypeInterventional
    Last Update Posted2025-10-16

    Study Overview

    Brief Summary

    Extensive research is being conducted in search of neuroprotective agents for possible use in the acute phase of stroke and agents that can be used for neurorepair in later stages of stroke. Several trials have been conducted and are in progress using different pharmacological agents, but none of the studies involve the stimulation of ETB receptors to treat cerebral ischemic stroke. Sovateltide (IRL-1620, PMZ-1620) has been effective in animal models of cerebral ischemic stroke. Its safety and tolerability have been demonstrated in a human phase I study with 7 subjects. Clinical phase II and III results indicate that sovateltide is a novel, first-in-class, highly effective drug candidate for treating cerebral ischemic stroke. Safety and significant efficacy in improving the National Institutes of Health Stroke Scale (NIHSS), Modified Rankin scale (mRS), and Barthel index (BI) obtained in phase II and III studies in patients with cerebral ischemic stroke in India are convincing and encouraged us to investigate its safety and efficacy in cerebral ischemic stroke patients in the United States. Therefore, the plan is to conduct a phase III clinical study to evaluate the safety and efficacy of sovateltide therapy along with standard of care in patients of acute ischemic stroke.

    To learn more, visitClinicalTrials.gov

    Posted by at No comments:
    Labels: , , , ,

    Friday, July 25, 2025

    Advances in clinical studies of peptide drugs in stroke disease

     Your competent? doctor has been working on peptides for over a decade, right? Oh NO, INCOMPETENCE REIGNED AND NOTHING WAS DONE, CORRECT?

    Let's see EXACTLY HOW LONG AND IN WHAT YOUR DOCTOR IS INCOMPETENT!
  • peptide (16 posts to January 2012)
  • nerinetide (10 posts to February 2020)

    • Efficacy and Safety of Sovateltide in Patients with Acute Cerebral Ischaemic Stroke: A Randomised, Double-Blind, Placebo-Controlled, Multicentre, Phase III Clinical Trial

     November 2024

    Advances in clinical studies of peptide drugs in stroke disease


    https://doi.org/10.1016/j.bbadis.2025.167970Get rights and content

    Highlights

    • •
      Peptide drugs exhibit tremendous potential in stroke treatment, characterized by high specificity, and low toxicity.
    • •
      Multiple peptide drugs (such as CN-105, Nerinetide, and Sovateltide) show promising therapeutic prospects in clinical trials for stroke treatment.
    • •
      Peptide drugs still face challenges in stability, delivery, and bioavailability.
    • •
      Peptide drugs represent an innovative frontier in stroke treatment, offering potential new therapeutic options for patients.

    Abstract

    Stroke remains a leading cause of death and disability globally, with limited treatment options currently available. Fortunately, peptide drugs have emerged as promising candidates for treating central nervous system disorders, including stroke. They offer high specificity, low toxicity, and efficient blood-brain barrier penetration, demonstrating significant therapeutic potential. This review systematically introduces several promising peptide drugs, analyzing their mechanisms, therapeutic efficacy in clinical trials, and potential applications. It also addresses critical challenges in peptide drug development for stroke therapy, such as optimizing dosing strategies, enhancing stability, and improving delivery systems. The analysis of current clinical evidence suggests that peptide-based therapeutics represent a promising frontier in stroke treatment, potentially offering new therapeutic options for patients. This comprehensive review not only highlights the current status of peptide drug development but also provides insights into future directions for advancing stroke therapy.

    Introduction

    Stroke threatens human health and can lead to death and long-term disability [1]. The World Stroke Organization (WSO) stated that stroke is the second reason cause of death globally and the third reason cause of death and disability in its 2022 Global Stroke Fact Sheet [2]. And in 2019, the estimated global cost of stroke exceeded $891 billion, accounting for 1.12 % of the worldwide GDP [2]. The American Heart Association (AHA) also indicated that the prevalence of stroke in the United States is estimated to be 3.3 %, with approximately 9.4 million Americans aged 20 and older self-reporting a history of stroke in its 2023 Stroke Statistics Report [3]. One study suggests an additional 3.4 million adults aged 18 and older would have a stroke in the U.S. by 2030, an increase of 20.5 % from 2012 [2]. The mechanisms of neurological injury in stroke are complex, including cellular mitochondrial dysfunction [4], neuroinflammation [5], excitotoxicity [6], oxidative stress [7], and apoptosis [8]. Current stroke management strategies predominantly rely on time-sensitive interventional approaches, including intravenous thrombolysis (IVT), intra-arterial thrombolysis (IAT), and endovascular thrombectomy (EVT). However, a critically narrow therapeutic window significantly constrains their clinical efficacy [9,10]. That means only a small fraction of stroke patients could get immediate treatment, while the overwhelming majority are precluded from these therapies. This clinical landscape shows the pressing necessity for the development of innovative neuroprotective strategies that can expand the therapeutic window. Consequently, the exploration of targeted neuroprotective agents has become a research priority to mitigate acute neurological damage and provide other effective programs for stroke treatment [11]. This review briefly introduces peptide drugs and summarizes the progress of clinical studies of peptide drugs as neuroprotective agents in stroke.

    Access through your organization

    Posted by at No comments:
    Labels: , , , , ,
    Subscribe to: Posts (Atom)